Tele: 561.316.3330
Breaking Medical Device News

Sunday, October 17, 2021



Wally Renne, DMD & Founder of the MOD Institute, Appointed to VP of Clinical Strategy Desktop Health

Michael Jafar, President and CEO of Desktop Health: “Dr. Renne is an outstanding addition to the growing Desktop Health team. He brings a deep understanding of the dental industry and he aligns with our mission of providing innovative personalized healthcare products and driving clinical excellence"

Desktop Health, a healthcare business committed to developing 3D printing and biofabrication solutions for personalized medicine, today announced the appointment of Wally Renne, DMD, to Vice President of Clinical Strategy at Desktop Health. In this position, Dr. Renne will be responsible for advancing Desktop Health’s clinical strategy for 3D printing technology solutions in digital dentistry.

In this new role, Dr. Renne will design and implement clinical studies that deliver on Desktop Health’s vision and address patient needs, as well as provide strategic direction for product development, education, and downstream commercial activities. He will also spearhead and direct multiple clinical programs, while guiding the larger strategy and clinical development plan for the global dental business.

“Dr. Renne is an outstanding addition to the growing Desktop Health team. He brings a deep understanding of the dental industry and he aligns with our mission of providing innovative personalized healthcare products and driving clinical excellence,” said Michael Jafar, President and CEO of Desktop Health. “With years of experience both as an active researcher and award-winning educator, Dr. Renne knows what it takes to deliver patient success and we’re thrilled to have him join our leadership team in this critical role.”

Dr. Renne is a global educator on digital dentistry and founder of the MOD Institute (Modern Optimized Dentistry) of Charleston, S.C., where he leads all learning and innovation initiatives at the organization. He is a contributing member of MOD Aesthetics, the private practice arm of MOD. He also recently served as a Professor and Assistant Dean of Innovation and Digital Dentistry at the Medical University of South Carolina and earned several national and regional awards for his efforts both pre-clinically and clinically. An active dental researcher, he has published more than 30 studies on scan and milling accuracy using various systems. Dr. Renne also has several patents including a patent for a platform of long-term antimicrobial dental materials.

“I am thrilled to be part of an organization that is laser-focused on providing leading innovation and education to dental practitioners, while also ensuring that clinical excellence is at the core of everything we do,” said Dr. Renne. “I’m inspired by the fact that Desktop Health has ambitious goals in all areas of digital dentistry. Its track record and reputation are already delivering clinical excellence in the field of dentistry and is quickly becoming an important and valued partner by clinicians both in the U.S. and abroad.”

Other Articles

Ganymed Robotics Awarded a €2.5M Grant from the EC through the EIC Accelerator Program

Ganymed Robotics is developing a radically new approach to surgical robotics by combining computer vision, a branch of artificial intelligence, and mechatronics.

Global Healthcare Exchange Announces Acquisition of Explorer Surgical

Explorer Surgical will operate as a wholly-owned subsidiary of GHX.

Arlington Scientific Broadens Product Portfolio and Further Expands its Product Offering Through the acquisition of Non-Mammalian Blocking Buffers

Arlington Scientific, Inc. (ASI) is pleased to announce that it has acquired the non-mammalian blocking buffer product line from Clark McDermith, former owner of...

Laborie Medical Technologies Acquires Pelvalon

Laborie was represented by Piper Sandler (financial advisor) and Simpson Thacher & Bartlett LLP (legal advisor). Pelvalon was represented by J.P. Morgan Securities LLC (financial advisor) and Dorsey & Whitney LLP (legal advisor).

Eliaz Therapeutics is Raising Capital

The XGAL3® therapeutic apheresis device is the early-mover for the treatment of AKI. ETI has demonstrated significant survival benefits in preclinical models and their prototype device has successfully removed GAL-3 from human blood plasma.

Veranex Announces Acquisition of IMMR

IMMR, a leading preclinical science organization that provides preclinical research, pathology evaluation and surgical training services to medical technology innovators.

By using this website you agree to accept Medical Device News Magazine Privacy Policy